The heart team at Blackpool Victoria Hospital in England had already decided this operation would be difficult. Their patient, a 72-year-old woman, had severe low-flow aortic stenosis, a left ventricular ejection fraction of 15%, and a systemic vasculitis that made her blood vessels a question mark. What they did not anticipate was the color.
Once the ascending aorta was open, the tunica intima, its innermost lining, was distinctly blue, the discoloration extending toward the aortic valve. The outer layer looked normal. The surgeons proceeded, implanted the valve, and later wrote that they could find no prior report of this finding in a patient with Churg-Strauss syndrome. The case report appeared this month in the Journal of Surgical Case Reports, from clinicians at Blackpool Teaching Hospitals, Yeovil District Hospital, the University of Khartoum and St. George's University.
A Blue Lining, a Normal Outer Wall and No Tissue to Test
Churg-Strauss syndrome, now more often called eosinophilic granulomatosis with polyangiitis, is a rare vasculitis that attacks small and medium-sized vessels. The report puts its prevalence at 10.7 to 14 cases per million, with no gender or ethnic predisposition. Large-vessel involvement, and the aorta in particular, is described in the literature as exceedingly rare and poorly documented. Aortic abnormalities are more the territory of Takayasu arteritis or giant cell arteritis.
The authors offer three hypotheses for the discoloration and are careful to label the mechanism speculative: chronic vascular inflammation from the vasculitis itself, vessel injury from immune complex deposition, or hemosiderin deposition, the iron pigment left behind after bleeding into tissue.
They cannot go further, and they explain why. The operation used a transverse aortotomy, which does not involve removing any aortic wall, so no specimen existed to send to pathology. The color was never confirmed under a microscope. They also concede that the discoloration, clearly visible to the operating team, reproduces only faintly in their single intraoperative photograph under theater lighting, and they included a magnified panel to help readers see it.
Her Ejection Fraction Fell from 50% to 15% in Ten Months
The patient's referral began with a year of worsening breathlessness and fatigue. Six months in, both feet began swelling, and echocardiography found significant aortic stenosis.
Her history was long: atrial fibrillation, mild coronary artery disease, a heart attack in 2017, high blood pressure, high cholesterol, heart failure, bronchiectasis, type 1 diabetes, osteoarthritis and depression, plus peripheral neurovasculitis from her Churg-Strauss syndrome, managed with prednisolone and mycophenolate mofetil. Bloodwork showed a normal white cell count and a normal eosinophil count alongside perinuclear antineutrophil cytoplasmic antibodies.
The number that stands out is the slide in pump function. Her ejection fraction measured 15% before surgery, down from 50% ten months earlier, with an aortic valve area of 0.7 square centimeters. The authors read that trajectory as a demonstration of how quickly the disease can compromise cardiac function, and as an argument for timely intervention.
Cardiac involvement is a recognized and serious feature. The report cites literature showing it in up to roughly 60% of patients when sensitive imaging is used, and identifies it as a leading cause of death from the disease. A French retrospective series documented the range of cardiac findings. Valve disease is less common, and mitral regurgitation, not aortic stenosis, is what usually appears.
Why the Heart Team Chose Open Surgery Over a Catheter
Transcatheter aortic valve replacement avoids cardiopulmonary bypass, a theoretical advantage in someone with an ejection fraction of 15%. The team went the other way and set out its reasoning.
At 72, she sat at the younger end of the group in whom a surgical bioprosthesis offers durability advantages. Her low-flow, low-gradient stenosis with severely depressed function is a complex subgroup regardless of approach. Most decisive was her documented peripheral neurovasculitis, which raised concern about whether her peripheral vessels could tolerate large-bore access through the groin, and about the integrity of the aortic wall itself. The intraoperative finding, as they note, reinforced that concern after the fact.
They implanted a 23 mm rapid-deployment valve specifically to limit cross-clamp and bypass times. Postoperative imaging confirmed improved valve function and ejection fraction. The decision followed the kind of multidisciplinary review that the 2020 ACC/AHA valvular heart disease guideline calls for.
A Tamponade on Day Six and 34 Days in Intensive Care
On the sixth day after surgery, she had a peri-arrest event. An emergency repeat sternotomy found cardiac tamponade, blood compressing the heart, which was evacuated.
She spent 34 days in the cardiothoracic intensive care unit before transfer for rehabilitation. The authors attribute the long course to three converging factors: baseline pump function that predisposed her to low cardiac output and prolonged drug support, the day-six setback, and her vasculitis plus chronic immunosuppression slowing recovery. Patients with this disease are recognized as prone to pericardial fluid and tamponade, a point the report supports with a meta-analysis of 62 published cases of cardiac involvement, though data on perioperative complications are scarce enough that prediction is guesswork. A separate case series of valve replacement in a related vasculitis records a comparable surprise, a third-degree heart block after surgery.
She was discharged in stable condition and died some time afterward. The authors state that they were unable to reach her relatives despite repeated attempts and that the report has been anonymized accordingly.
As a single case with no tissue diagnosis, this cannot establish what caused the blue lining or how often it might occur. The authors' request is simple: report similar findings, with microscopic examination of the tissue where possible.
Key Questions Answered
What did the surgeons see?
Once the ascending aorta was opened during valve replacement, its innermost lining was distinctly blue, with the discoloration extending toward the aortic valve. The outer layer of the vessel looked normal.
Why is that finding notable?
The authors could find no previous report of blue discoloration of the ascending aortic lining in a patient with Churg-Strauss syndrome, and large-vessel involvement in this disease is itself described as exceedingly rare.
Do doctors know what caused it?
No. Chronic inflammation, immune complex deposition, and hemosiderin deposition are all raised as possibilities. No aortic tissue was available for pathology because the surgical technique does not remove any of the wall.
Did the discoloration change the operation?
It did not alter the surgical approach. The team completed the valve replacement as planned and raised concerns about the vessel's structural integrity afterward.
What is Churg-Strauss syndrome?
A rare systemic vasculitis, also called eosinophilic granulomatosis with polyangiitis, marked by eosinophilic inflammation and vessel damage, often beginning with asthma or allergic rhinitis. Heart involvement is common and a leading cause of death from the disease.
What does this case not tell us?
It is one patient with no tissue confirmation, so it cannot show what produced the color, how often it occurs, or whether it predicts surgical risk. The authors call for further reports with microscopic confirmation.
